Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.80 |
| ▸ | ARG2 | P78540 | 4/20 | 0.50 |
| ▸ | ARG1 | P05089 | 3/20 | 0.50 |
| ▸ | NOS2 | P35228 | 5/20 | 0.49 |
| ▸ | NOS1 | P29475 | 4/20 | 0.49 |
| ▸ | NOS3 | P29474 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL30531666 | 1.00 | GSR (0.80) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL30585523 | 1.00 | GSR (0.80) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL7706799 | 1.00 | GSR (0.80) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL4667085 | 0.94 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL4667086 | 0.94 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Ornithine Aketoglutarate SCHEMBL25380963 | 0.92 | GSR (0.67) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL5581427 | 0.90 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL15753994 | 0.90 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL1696587 | 0.90 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL302610 | 0.90 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120022522-A | Drug-loaded microneedle, drug-loaded microneedle patch and electrically-controlled drug release microneedle system | 成都邦迈医创科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119899273-A | Preparation method and application of human PGK1 site 131 lysine lactate modified antibody | 中国人民解放军空军军医大学 | 2025-04-29 | — | — | CN | claimed |
| CN-119798370-A | Specific anti-ITSN 1-S-K1068 lysine lactic acid antibody and preparation method and application thereof | 天津市肿瘤医院（天津医科大学肿瘤医院） | 2025-04-11 | — | — | CN | claimed |
| CN-119504970-A | Target spot for pancreatic cancer treatment and application thereof | 山东大学 | 2025-02-25 | — | — | CN | claimed |
| US-12178874-B2 | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof | JUST-EVOTEC BIOLOGICS, INC. (US) | 2024-12-31 | — | — | US | claimed |
| CN-118050511-B | Target spot for digestive tract tumor treatment and application thereof | 山东大学 | 2024-09-17 | — | — | CN | claimed |
| CN-118050511-A | Target spot for digestive tract tumor treatment and application thereof | 山东大学 | 2024-05-17 | — | — | CN | claimed |
| CN-116804055-A | Antibodies modified by lactic acid of lysine at 477 position of nucleolin, preparation method and application thereof | 中国人民解放军空军军医大学 | 2023-09-26 | — | — | CN | claimed |
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | AMGEN INC. | 2023-03-16 | — | — | US | claimed |
| EP-4103235-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | Amgen Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| CN-115279404-A | Formulation of human anti-TSLP antibodies and methods of treating inflammatory diseases | 安进公司 | 2022-11-01 | — | — | CN | claimed |
| WO-2021163504-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | AMGEN INC. (US) | 2021-08-19 | — | — | WO | claimed |
| EP-1165821-A1 | METHOD FOR TREATING ORGANIC WASTE PRODUCTS | AGRO-FERM A/S (DK) | 2002-01-02 | — | — | EP | claimed |
| WO-2000056912-A1 | METHOD FOR TREATING ORGANIC WASTE PRODUCTS | AGRO-FERM A/S (DK) | 2000-09-28 | — | — | WO | claimed |
| US-5326566-A | As solvents, water or oil soluble surfactants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-07-05 | — | — | US | claimed |
| CN-122005574-A | Application of monocarboxylic acid transporter 1 inhibitor in preparation of medicines for preventing, relieving and/or treating pancreatic cancer | 华中科技大学同济医学院附属协和医院 | 2026-05-12 | — | — | CN | disclosed |
| CN-121673405-A | CISD1 protein K68 site lysine lactate modified antibody, and preparation method and application thereof | 中国人民解放军空军军医大学 | 2026-03-17 | — | — | CN | disclosed |
| EP-0673647-A1 | Dermatological composition containing lactic acid salt | Bristol-Myers Squibb Company (US) | 1995-09-27 | — | — | EP | disclosed |
| US-5420106-A | Method and composition having enhanced alpha-hydroxy acid skin permeation and retention | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-05-30 | — | — | US | disclosed |
| US-4986999-A | PRODUCT FROM ENZYMATIC HYDROLYSIS OF PROTEINS EXTRACTED FROM FISH OR MEATS | NIHON BUSSAN KABUSHIKI KAISHA (JP) | 1991-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | TSLP, IL5, ORAI1 | GSR 4256/4885ARG2 2715/4885ARG1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.